Pharmacodynamic Effects of Single Doses of Rabeprazole 20 Mg And

Total Page:16

File Type:pdf, Size:1020Kb

Pharmacodynamic Effects of Single Doses of Rabeprazole 20 Mg And Alimentary Pharmacology & Therapeutics Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn S.WARRINGTON*,K.BAISLEY*,D.LEE*,K.LOMAX ,B.DELEMOSà,M.BOYCE*&A.MOROCUTTI§ *Hammersmith Medicines Research SUMMARY Ltd, Central Middlesex Hospital, London, UK; Medical Affairs, Eisai Background Inc., Teaneck, NJ, USA; àPriCara, Unit Rabeprazole and pantoprazole are both used for symptomatic treatment of Ortho-McNeil Inc., Raritan, NJ, USA; §Medical Affairs, Eisai Ltd, of gastro-oesophageal reflux disease (GERD). Speed and duration of acid London, UK suppression and intensity of effect after a single dose may be important pharmacodynamic properties in clinical use. Correspondence to: Dr S. Warrington, Hammersmith Aim Medicines Research Ltd, Central Middlesex Hospital, Acton Lane, To compare antisecretory effects of single doses of rabeprazole and pan- London NW10 7NS, UK. toprazole in patients with GERD and a history of nocturnal heartburn. E-mail: [email protected] Methods An open-label, randomized, two-way crossover, clinical pharmacology Publication data Submitted 30 August 2006 study was conducted. Twenty-nine Helicobacter pylori-negative GERD First decision 5 September 2006 patients (17 men, mean age 44 years), with a history of nocturnal heart- Resubmitted 18 October 2006 burn (mean frequency 4.7 episodes/week), received a single dose of Accepted 6 November 2006 rabeprazole 20 mg or pantoprazole 40 mg, with a 14-day ‘washout’. In- tragastric pH was recorded continuously from 24 h before to 24 h after dosing. Results Mean area under the intragastric pH–time curve (AUC) was significantly higher after dosing with rabeprazole 20 mg than with pantoprazole 40 mg in all time intervals analysed, including night (P £ 0.02). Mean percentage time with pH > 3 and >4 was significantly greater after rabeprazole than pantoprazole in all time intervals (P £ 0.004). Conclusion In GERD patients with nocturnal heartburn, a single oral dose of rabep- razole 20 mg increased intragastric pH more than pantoprazole 40 mg did throughout the 24 h after dosing. Aliment Pharmacol Ther 25, 511–517 ª 2007 The Authors 511 Journal compilation ª 2007 Blackwell Publishing Ltd doi:10.1111/j.1365-2036.2006.03196.x 512 S. WARRINGTON et al. mass index of 18.0–30.9 kg/m2 and were either non- INTRODUCTION smokers or smoked £5 cigarettes/day. All were negat- Proton pump inhibitors (PPIs) are now considered to be ive for H. pylori by serology and 13C-urea breath test the first-line treatment for gastro-oesophageal reflux (Helicobacter diagnostic test kit; Kestrel Healthcare Ltd, disease (GERD). Treatment efficacy is strongly correla- Basingstoke, UK). They were not allowed to take pre- ted with the degree and duration of acid suppression scription medicines during the 28 days before the start 1,2 over 24 h. GERD patients who experience nocturnal of the study, but an H2-blocker or PPI was allowed up symptoms may experience profound impairment of to 14 days before the start of the study. Oral contra- physical health, daytime function and emotional well- ceptives were allowed in women. Over-the-counter being, as demonstrated by measures of mental and medicines were not allowed within 7 days before the physical well-being, pain and oesophageal erosion.3 start of the study (with the exception of paracetamol), Suppression of nocturnal acidity may be particularly but antacid preparations were allowed up to 3 days important for symptom relief in such patients. before the start of the study. There are pharmacological differences among the PPIs after a single dose that may have implications for Ethics their clinical efficacy. For example, although all PPIs are strong inhibitors of gastric acid at steady state, The study proposal was reviewed and approved by the rabeprazole may suppress acid output more potently Brent Medical Ethics Committee. All subjects gave after a single dose.4,5 Such pharmacological differ- written informed consent. ences may also have implications for the control of nocturnal acidity. Study design Both pantoprazole and rabeprazole are used to treat patients with night-time reflux symptoms. Some This study was an open-label, randomized, two-way authors have suggested that, as pantoprazole has a crossover design. Subjects were resident at the study longer half-life than many other PPIs, it might be unit for two 3-day study periods separated by a wash- more effective at relieving nocturnal symptoms.3 out period of at least 14 days. After an overnight fast, Our study was designed to compare the antisecretory subjects were given a single dose of either rabeprazole effects of single doses of rabeprazole 20 mg and pan- 20 mg or pantoprazole 40 mg, with 100 mL of water. toprazole 40 mg in Helicobacter pylori-negative sub- The order of treatment with rabeprazole or pantopraz- jects who had a clinical diagnosis of GERD and a ole was randomized using an SAS program (SAS for history of nocturnal heartburn. Twenty milligrams of Windows, version 6.12; SAS Institute, Cary, NC, USA). rabeprazole and 40 mg of pantoprazole are the recom- Intragastric pH was measured from 24 h before dosing mended daily doses of each drug for oesophagitis heal- (day 0) until 24 h after dosing. Subjects had standard ing and symptom relief. Although there are numerous meals and drinks at 1, 4 and 10 h, and went to bed studies of the effect of PPIs on intragastric pH at steady (became supine) at around 14 h, after dosing on day 1, state, there are few published reports of the pharmaco- and at the corresponding times on day 0. Alcoholic dynamic effects on the first day of therapy. drinks, caffeinated beverages, smoking, grapefruit and its juice, Seville orange and its juice, and strenuous exercise were not allowed during the interval from MATERIALS AND METHODS 48 h before day 0 until the end of each study period. On day 2, 24 h after the dose of study medication, the Subjects intragastric pH measurements were stopped, the naso- Subjects were H. pylori-negative men or women aged gastric electrode was removed and patients were dis- 18–70 years, with a clinical diagnosis of GERD and a charged after a brief physical examination, if all was history of nocturnal heartburn (‡1 episode/week). Sub- well. They returned 5–10 days after the last dose of jects were interviewed regarding the frequency of their study drug for a follow-up medical examination. symptoms. Endoscopy was not required as an entry Adverse events were recorded throughout the study. criterion. Subjects were deemed otherwise healthy on Subjects were questioned about adverse events at the basis of medical history, medical examination, 12- regular intervals during their stay at the study unit, lead ECG and laboratory safety tests. They had a body and at follow-up. ª 2007 The Authors, Aliment Pharmacol Ther 25, 511–517 Journal compilation ª 2007 Blackwell Publishing Ltd RABEPRAZOLE VS. PANTOPRAZOLE IN GERD PATIENTS 513 contained fixed effects for sequence, period and treat- Measurement of intragastric pH ment, and random effects for subject nested within Intragastric pH was recorded continuously on days 0 sequence. The response variable was AUC or percent- and 1. On day 0, after anaesthetizing the subject’s age time with pH > 3 or >4 on day 1; the day 0 value nostril with 1% lidocaine hydrochloride spray, we was included in the model as a covariate. Day 1 AUCs inserted a disposable antimony internal reference pH were log-transformed to conform to a normal distribu- electrode with surface markings of 1 cm (Zinetics tion, except for AUC11)14, which did not require trans- Medical, Salt Lake City, UT, USA). pH was monitored formation. Day 1 percentage time pH > 3 and >4 was during passage of the electrode down the oesophagus, arcsin-transformed. Statistical inference was based on through the gastro-oesophageal sphincter and into the transformed variables. the stomach. We confirmed entry of the electrode The study was powered to test the hypothesis of no into the stomach by a sharp fall in pH, usually to difference in AUC0)24 between rabeprazole and pan- less than 3.2. Next, the electrode was withdrawn toprazole. Based on variability data obtained from a slowly to about 40 cm; a sharp rise in pH identified similar study in healthy volunteers,5 a within-subject the point at which the electrode crossed the sphinc- standard deviation of intragastric pH AUC0)24 of about ter. We then advanced the electrode slowly to a final 40 000 pH units/s was assumed. It was thus estimated position 8–10 cm (depending on the subject’s height) that 30 evaluable patients would have 90% power to beyond the point at which the pH fell below 3. Intra- detect a difference of 34 588 pH units/s in AUC0)24 gastric pH was recorded every 6 s using a Flexilog between rabeprazole and pantoprazole, at a 5% signi- 2020 96-h recorder (Oakfield Instruments, Oxford, ficance level. If within-subject variability in intragas- UK), which had been precalibrated using buffers of tric pH AUC0)24 was as high as 47 000 pH units/s, pH 1.1 and 6.7, before passage of the electrode. The then 30 evaluable patients would give 80% power to recorded data were uploaded to a computer using detect the same difference. Flexisoft II software (Oakfield Instruments). RESULTS Statistical analysis Subjects The primary efficacy variable was the area under the intragastric pH–time curve during the period from Thirty-one subjects entered the study. One man took dosing on day 1 until 24 h afterwards (AUC0))24). The an H2-blocker 5 days before dosing, and one man had primary null hypothesis was that there is no difference to repeat period 1 because of a failure of the pH recor- between rabeprazole and pantoprazole in intragastric der; both subjects were excluded from the per-protocol pH AUC0)24 on day 1.
Recommended publications
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
    [Show full text]
  • Proton Pump Inhibitors
    MEDICATION POLICY: Proton Pump Inhibitors Generic Name: Proton Pump Inhibitors Preferred: Esomeprazole (generic), Lansoprazole (generic), Omeprazole (generic), Therapeutic Class or Brand Name: Proton Pantoprazole (generic), and Rabeprazole Pump Inhibitors (generic) Applicable Drugs (if Therapeutic Class): Non-preferred: Aciphex® (rabeprazole), Esomeprazole (generic), Lansoprazole Dexilant® (dexlansoprazole), Nexium® (generic), Omeprazole (generic), Pantoprazole (esomeprazole), Not Medically Necessary: (generic), and Rabeprazole (generic). Omeprazole/Sodium Bicarbonate (generic), Aciphex® (rabeprazole), Dexilant® Zegerid® (omeprazole/sodium bicarbonate). (dexlansoprazole), Nexium® (esomeprazole), Prevacid® (lansoprazole), Prilosec® Date of Origin: 2/1/2013 (omeprazole), and Protonix® (pantoprazole). Date Last Reviewed / Revised: 12/23/2020 Omeprazole/Sodium Bicarbonate (generic), Zegerid® (omeprazole/sodium bicarbonate). Policy also applies to any other Proton Pump Inhibitors not listed. GPI Code: 4927002000, 4927002510, 4927004000, 4927006000, 4927007010, 4927007610, 4999600260 PRIOR AUTHORIZATION CRITERIA (May be considered medically necessary when criteria I and II are met) I. Documented diagnosis of one of the following A through G: A. Gastroesophageal reflux disease (GERD). B. Erosive esophagitis. C. Gastric ulcers. D. Risk reduction of NSAID-associated gastric ulcer. E. Duodenal ulcers. F. Eradication of H. pylori. G. Hypersecretory conditions II. Non-preferred PPIs require documented trials and failures of all generic PPIs. EXCLUSION
    [Show full text]
  • Comparison of the Efficacies of Proton Pump Inhibitors and H2 Receptor Antagonists in On-Demand Treatment of Gastroesophageal Reflux Disease
    8 ORIGINAL ARTICLE COMPARISON OF THE EFFICACIES OF PROTON PUMP INHIBITORS AND H2 RECEPTOR ANTAGONISTS IN ON-DEMAND TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE Nesibe Vardı1, Emine Köroglu2, Sabah Tüzün3, Can Dolapçıoğlu4, Reşat Dabak5 1Kilimli No: 8104005 Dikmeli Family Health Centre, Duzce, Turkey 2Department of Gastroenterology, Kartal Dr.Lütfi Kırdar Training and Research Hospital, Istanbul, Turkey 3Department of Family Medicine, Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul, Turkey Abstract Objective: On-demand treatment protocols in the maintenance treatment of gastroesophageal reflux disease (GERD) are cost-efficient and easy-to-use treatments.This study aimed to compare the efficacies of H2 receptor antagonists (H2RA) and proton pump inhibitors (PPI) in on-demand treatment of GERD. Methods: Patients with persistent GERD symptoms were enrolledbetween January-November 2015 and were ran- domly separated into two equal groups. The patients in the first group were commenced on ranitidine 300 mg as H2RA and the patients in the second group were commenced on pantoprazole 40 mg. A 4-point Likert-type scale generated by the researchers was applied to evaluate the frequencies of reflux symptoms and their impacts on activities of life and business life. Results: Fifty-two patients were included, of whom 26 (50.0%) were in the PPI group and 26 (50.0%) were in the H2RA group. There were no significant differences between the study groups both before and after treatment in terms of the severity of reflux symptoms. There were significant decreases in the H2RA group in terms of the domains of retrosternal burning sensation, regurgitation, nausea and vomiting, and burping (p=0.036, p=0.027, p=0.020, and p=0.038, respectively).
    [Show full text]
  • Aciphex (Rabeprazole Sodium)
    ACIPHEXÔ çç \ a-sc -**feks\ (rabeprazole sodium) Delayed-Release Tablets DESCRIPTION The active ingredient in ACIPHEXÔ Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2- pyridinyl]-methyl] sulfinyl]-1H–benzimidazole sodium salt. It has an empirical formula of C18H20N3NaO3S and a molecular weight of 381.43. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural formula is: Na N O H3C O CH2 O CH3 S CH2 CH2 N CH2 N RABEPRAZOLE SODIUM ACIPHEXÔ is available for oral administration as delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium. Inactive ingredients are mannitol, hydroxypropyl cellulose, magnesium oxide, low-substituted hydroxypropyl cellulose, magnesium stearate, ethylcellulose, hydroxypropyl methylcellulose phthalate, diacetylated monoglycerides, talc, titanium dioxide, carnauba wax, and ferric oxide (yellow) as a coloring agent. NDA 20-973 (AciphexÔ ) 1 Annotated Package Insert March 5, 1999 CLINICAL PHARMACOLOGY Pharmacokinetics and Metabolism ACIPHEXTM delayed-release tablets are enteric-coated to allow rabeprazole sodium, which is acid labile, to pass through TM the stomach relatively intact. After oral administration of 20 mg ACIPHEX , peak plasma concentrations (Cmax) of rabeprazole occur over a range of 2.0 to 5.0 hours (Tmax). The rabeprazole Cmax and AUC are linear over an oral dose range of 10 mg to 40 mg.
    [Show full text]
  • Proton Pump Inhibitors
    Provider update Hot Tip: Proton pump inhibitors Your Amerigroup Community Care patients may experience a pharmacy claim rejection when prescribed nonpreferred products. To avoid additional steps or delays at the pharmacy, consider prescribing preferred products whenever possible. Utilization Management edits may apply to select preferred products. Coverage should be verified by reviewing the Preferred Drug List (PDL) on the Amerigroup provider website. The PDL is subject to change quarterly. Preferred products Nonpreferred products All brand and generic OTC strengths and All brand and generic prescription strengths formulations1 and formulations • OTC Zegerid (omeprazole-bicarbonate) • Zegerid (omeprazole-bicarbonate) OTC omeprazole-bicarbonate (generic OTC • Omeppi (omeprazole-bicarbonate) Zegerid) • Omeprazole-bicarbonate (generic Rx Zegerid) All brand and generic OTC product strengths and All brand and generic prescription product formulations1 See footnote for reference of strengths and formulations unless otherwise available OTC strengths3 noted • OTC esomeprazole DR (generic Nexium) • Aciphex (rabeprazole) • OTC lansoprazole DR (generic Prevacid) • Dexilant (dexlansoprazole) • OTC Nexium 24hr (esomeprazole) • Esomeprazole (generic Nexium) • OTC omeprazole (generic Prilosec) • Lansoprazole (Prevacid) • OTC Prevacid 24hr (lansoprazole) • Nexium (esomeprazole) • OTC Prilosec (omeprazole) • Omeprazole2 (generic Prilosec) • Pantoprazole (generic Protonix) • Prevacid (lansoprazole) • Prilosec (omeprazole) • Protonix (pantoprazole) • Rabeprazole
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • PHRP March 2015
    March 2015; Vol. 25(2):e2521518 doi: http://dx.doi.org/10.17061/phrp2521518 www.phrp.com.au Research Manual versus automated coding of free-text self-reported medication data in the 45 and Up Study: a validation study Danijela Gnjidica,b,i, Sallie-Anne Pearsona,c, Sarah N Hilmerb,d, Jim Basilakise, Andrea L Schaffera, Fiona M Blythb,f,g and Emily Banksg,h, on behalf of the High Risk Prescribing Investigators a Faculty of Pharmacy, University of Sydney, NSW, Australia b Sydney Medical School, University of Sydney, NSW, Australia c Sydney School of Public Health, University of Sydney, NSW, Australia d Royal North Shore Hospital and Kolling Institute of Medical Research, Sydney, NSW, Australia e School of Computing, Engineering and Mathematics, University of Western Sydney, NSW, Australia f Centre for Education and Research on Ageing (CERA), Concord Hospital, Sydney, NSW, Australia g The Sax Institute, Sydney, NSW, Australia h National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT i Corresponding author: [email protected] Article history Abstract Publication date: March 2015 Background: Increasingly, automated methods are being used to code free- Citation: Gnjidic D, Pearson S, Hilmer S, text medication data, but evidence on the validity of these methods is limited. Basilakis J, Schaffer AL, Blyth FM, Banks E. To examine the accuracy of automated coding of previously keyed Manual versus automated coding of free-text Aim: in free-text medication data compared with manual coding of original self-reported medication data in the 45 and Up Study: a validation study. Public Health handwritten free-text responses (the ‘gold standard’).
    [Show full text]
  • Acid-Reducing Medications: Interactions with Harvoni and Epclusa
    November 2016 | www.hepatitis.va.gov Acid-Reducing Medications: Interactions with Harvoni® and Epclusa® Sofosbuvir/Velpatasvir = Epclusa® Ledipasvir/Sofosbuvir = Harvoni® • Acid-reducing medications can decrease the effectiveness of Harvoni® and Epclusa® and could prevent successful cure. • Let your provider know if you are taking any acid-reducing medications—either prescribed to you or purchased over the counter. Types of Acid-Reducing What to Do if What to Do if Medications Taking Epclusa® Taking Harvoni® Antacids Separate taking the antacid and Separate taking the antacid and Epclusa® by 4 hours Harvoni® by 4 hours Combinations of aluminum, magnesium, and calcium. Brand names include: Alka-Seltzer® Maalox® Mylanta® Rolaids® TUMS® H2 Blockers Do not take more than the Do not take more than the recommended doses recommended doses Cimetidine (Tagamet®) Famotidine (Pepcid®) May take together with Epclusa® May take together with Harvoni® Nizatidine (Axid®) or 12 hours apart or 12 hours apart Ranitidine (Zantac®) Proton Pump Inhibitors (PPI) It is best to avoid PPIs during treat- It is best to avoid PPIs during ment with Epclusa®. If there are no treatment with Harvoni®. If there Esomeprazole (Nexium®) alternatives, follow these instructions: are no alternatives, follow these Lansoprazole (Prevacid®) instructions: Omeprazole (Prilosec®) Take Epclusa® with food Pantoprazole (Protonix®) Take the proton pump inhibitor 4 Take Harvoni® and the proton Rabeprazole (Aciphex®) hours after taking Epclusa® pump inhibitor at the same time in the morning after fasting overnight Do not take the proton pump (on an empty stomach) inhibitor at the same time as Epclusa® Do not take proton pump Do not take proton pump inhibitors inhibitors at more than the at more than the recommended dose recommended dose U.S.
    [Show full text]
  • Effectiveness and Tolerability of Different Recommended Doses Of
    www.nature.com/scientificreports OPEN Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Received: 26 April 2016 Accepted: 15 December 2016 Meta-Analysis and GRADE system Published: 19 January 2017 Chao Zhang1, Joey S. W. Kwong2, Rui-Xia Yuan1,3, Hao Chen4, Chang Xu5, Yi-Pin Wang1, Gong-Li Yang6, Jin-Zhu Yan1, Le Peng1, Xian-Tao Zeng1, Hong Weng1, Jie Luo1 & Yu-Ming Niu1,6 Proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) are used for gastro- esophageal reflux disease (GERD); however, the clinical evidence for treatment is poor. We evaluated the effectiveness and tolerability of different doses of PPIs,2 H RAs and placebo in adults with GERD. Six online databases were searched through September 1, 2016. All related articles were included and combined with a Bayesian network meta-analysis from randomized controlled trials (RCTs). The GRADE systems were employed to assess the main outcome. Ninety-eight RCTs were identified, which included 45,964 participants. Our analysis indicated that the full/standard dose of esomeprazole at 40 mg per day was the most efficient in healing among nine different dosages of PPIs and2 H RAs. The main efficacy outcome did not change after adjustments for the area, age, level of disease from endoscopy, year of publication, pharmaceutical industry sponsorship, Intention-to-treat (ITT)/per-protocol (PP), withdrawal rate, pre-set select design bias, single blinded and unblinded studies, study origination in China, study arms that included zero events, inconsistency node or discontinued drug were accounted for in the meta-regressions and sensitivity analyses.
    [Show full text]
  • Proton Pump Inhibitors in Veterinary Medicine
    American Journal of Animal and Veterinary Sciences Review Proton Pump Inhibitors in Veterinary Medicine 1Oguzhan Yavuz and 2Handan Hilal Arslan 1Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey 2Department of Internal Medicine, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey Article history Abstract: Inhibition of gastric acid secretion is necessary to treat many Received: 01-04-2017 gastrointestinal diseases. Proton Pump Inhibitors (PPIs) are very effective Revised: 02-06-2017 drugs, used for gastric acid inhibition and therapy of important erosive and Accepted: 23-06-2017 non-erosive gastrointestinal disorders in animals as well as humans. In this review, general properties of PPIs, their mode of action, pharmacokinetics, Corresponding Author: OguzhanYavuz efficacy, adverse effects, drug interactions and clinical and alternative uses Department of Pharmacology in veterinary medicine were evaluated. and Toxicology, Faculty of Veterinary Medicine, Keywords: Gastrointestinal Disorders, Proton Pump Inhibitors, Veterinary OndokuzMayis University, Medicine Samsun, Turkey Tel: 00903623121919/2830 Fax: 00903624576922 E-mail: [email protected] Introduction All clinically used PPIs contain a pyridyl methylsulfinyl benzimidazole group and differ only type Gastric acid is the secretion of parietal cells of of substituents on the pyridine and benzimidazole rings stomach and it is controlled by paracrine, endocrine and + + (Kosma et al ., 2016). Some important physicochemical neuronal systems. An important enzyme, H /K ATPase, properties of PPIs are shown in Table 1. is the main actor to pump hydrogen ions into the + + stomach lumen (H /K proton pump) (Shin and Sachs, Mode of Action 2008; Hori et al ., 2011; Garcia-Mazcorro et al ., 2012).
    [Show full text]
  • Early Effects of Oral Administration of Omeprazole and Roxatidine on Intragastric Ph
    Iida et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2012 13(1):29-34 29 Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: [email protected] Early effects of oral administration of omeprazole and roxatidine on intragastric pH Hiroshi IIDA1, Shingo KATO1, Yusuke SEKINO1, Eiji SAKAI1, Takashi UCHIYAMA1, Hiroki ENDO1, Kunihiro HOSONO1, Yasunari SAKAMOTO1, Koji FUJITA1, Masato YONEDA1, Tomoko KOIDE1, Hirokazu TAKAHASHI1, Chikako TOKORO1, Ayumu GOTO1, Yasunobu ABE1, Noritoshi KOBAYASHI1, Kensuke KUBOTA1, Eiji GOTOH2, Shin MAEDA1, Atsushi NAKAJIMA1, Masahiko INAMORI†‡1,3 (1Gastroenterology Division, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (2Department of Medical Education, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (3Office of Postgraduate Medical Education, Yokohama City University Hospital, Yokohama 236-0004, Japan) †E-mail: [email protected] Received Mar. 14, 2011; Revision accepted Aug. 30, 2011; Crosschecked Dec. 2, 2011 Abstract: Objective: The ideal medication for the treatment of acid-related diseases, e.g., peptic ulcers, stress- related gastric bleeding, functional dyspepsia, and gastroesophageal reflux disease, should have a rapid onset of action to promote hemostasis and relieve the symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of a proton pump inhibitor, omeprazole 20 mg, and an H2-receptor antagonist, roxatidine 75 mg. Methods: Ten Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 6 h after single oral admini- stration of omeprazole 20 mg and roxatidine 75 mg.
    [Show full text]
  • (Rabeprazole Sodium) Delayed-Release Tablets ACIPHEX Is a Medicine Called a Proton
    PATIENT INFORMATION ACIPHEX® (a-se-feks) (rabeprazole sodium) Delayed-Release Tablets READ THE PATIENT INFORMATION THAT COMES WITH ACIPHEX BEFORE YOU START TAKING IT AND EACH TIME YOU GET A REFILL.THERE MAY BE NEW INFORMATION.THIS LEAFLET DOES NOT TAKE THE PLACE OF TALKING TO YOUR DOCTOR ABOUT YOUR MEDICAL CONDITION OR TREATMENT. WHAT IS ACIPHEX? ACIPHEX is a medicine called a proton pump inhibitor or an “acid pump inhibitor”. This means it reduces the amount of acid that is made by your stomach. ACIPHEX is used in adults: • for the short-term (4 to 8 weeks) treatment in the healing and symptom relief of damaging (erosive) Gastroesophageal Reflux Disease (GERD). • to maintain healing of damage (erosions) and relief of heartburn symptoms with GERD. ACIPHEX has not been studied for treatment lasting longer than 12 months (1 year). • for the treatment of day-time and night-time heartburn and other symptoms that happen with GERD. • for short-term treatment (up to 4 weeks) in the healing and relief of stomach-area (duodenal) ulcers. The duodenal area is the area where food passes when it leaves the stomach. The main symptom of a duodenal ulcer is a steady pain in the stomach area. • with certain antibiotic medicines for the treatment of an infection caused by bacteria called H. pylori. Sometimes H. pylori bacteria can cause duodenal ulcers. The infection needs to be treated to prevent the ulcers from coming back. • for the long-term treatment of conditions where your stomach makes too much acid. This includes a condition called Zollinger-Ellison syndrome.
    [Show full text]